Findings and Methodology
The 2023 Health Care in Focus insights are based on data collected from two December 2022 surveys conducted by Ipsos on behalf of Evernorth. In total, 3002 consumers, 575 employers, and 75 health plan leaders were surveyed.
Up to
13-20%
savings with many biosimilars over their reference product
Faster speed to care lowers costs and improves outcomes in the cancer journey.
Diagnosing patients faster is one of the most effective ways to improve outcomes in oncology. It not only lowers costs, but can provide lifesaving time for cancer patients.
On average
13% - 20%
days from screening to diagnosis.
CASE STUDY
Findings and Methodology
The 2023 Health Care in Focus insights are based on data collected from two December 2022 surveys conducted by Ipsos on behalf of Evernorth. In total, 3002 consumers, 575 employers, and 75 health plan leaders were surveyed.
3% - 10%
The 2023 Health Care in Focus insights are based on data collected from two December 2022 surveys conducted.